Ultraviolet A1 phototherapy: one center's experience

Sasi Kiran Attili; Robert S. Dawe; Sally H. Ibbotson

doi:10.4103/0378-6323.182805

Ultraviolet A1 phototherapy: one center's experience

Sasi Kiran Attili (Lead / Corresponding author), Robert S. Dawe, Sally H. Ibbotson

Undergraduate Medicine

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

507 Downloads (Pure)

Abstract

BACKGROUND: Ultraviolet A1(UVA1) phototherapy is increasingly being used in the treatment of morphea, atopic dermatitis, lupus and some other recalcitrant dermatoses. We present a retrospective review of our experience with this modality.

AIM: To evaluate the treatment response rates for various dermatoses and adverse effects of UVA1 phototherapy.

METHODS: We reviewed phototherapy notes along with electronic and/or paper case records for all patients treated with UVA1 phototherapy from October 1996 to December 2008.

RESULTS: A total of 269 patients (outcomes available for 247) had 361 treatment courses (treatment data available for 317 courses) over this period. We found phototherapy to be beneficial in 28 (53%) of 53 patients with atopic dermatitis and 19 (51%) of 37 patients with morphea. A beneficial outcome was recorded in all six (100%) cases of urticaria and six (85.7%) of seven patients treated for a polymorphic light eruption. Benefit was also recorded in systemic lupus erythematosus (8 (44.4%) of 18), lichen sclerosus (6 (42.9%) of 14), mastocytosis (2 (33.3%) of 6), necrobiosis lipoidica (4 (30.8%) of 13), granuloma annulare (2 (25%) of 8), scleroderma (2 (22.2%) of 9) and keloids (1 (7.7%) of 13). Overall, treatment was well tolerated with no patients having to stop treatment due to adverse effects.

LIMITATIONS: This is a retrospective study with no control group. Subjective/recall bias is quite possible as a number of patients were followed up over the phone.

CONCLUSIONS: Our data suggest that ultraviolet A1 can be considered for the treatment of selected dermatoses. However, long-term malignancy risk is as yet unknown.

Original language	English
Pages (from-to)	60-65
Number of pages	6
Journal	Indian Journal of Dermatology, Venereology, and Leprology
Volume	83
Issue number	1
Early online date	23 May 2016
DOIs	https://doi.org/10.4103/0378-6323.182805
Publication status	Published - 2 Dec 2016

Keywords

Atopic dermatitis
morphea
phototherapy
ultraviolet A1

Access to Document

10.4103/0378-6323.182805Licence: CC BY-NC-SA

Final Published Version
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
Final published version, 875 KBLicence: CC BY-NC-SA

Cite this

@article{2701fdce04f44b3b9b79858d35e77a8d,

title = "Ultraviolet A1 phototherapy: one center's experience",

abstract = "BACKGROUND: Ultraviolet A1(UVA1) phototherapy is increasingly being used in the treatment of morphea, atopic dermatitis, lupus and some other recalcitrant dermatoses. We present a retrospective review of our experience with this modality.AIM: To evaluate the treatment response rates for various dermatoses and adverse effects of UVA1 phototherapy.METHODS: We reviewed phototherapy notes along with electronic and/or paper case records for all patients treated with UVA1 phototherapy from October 1996 to December 2008.RESULTS: A total of 269 patients (outcomes available for 247) had 361 treatment courses (treatment data available for 317 courses) over this period. We found phototherapy to be beneficial in 28 (53%) of 53 patients with atopic dermatitis and 19 (51%) of 37 patients with morphea. A beneficial outcome was recorded in all six (100%) cases of urticaria and six (85.7%) of seven patients treated for a polymorphic light eruption. Benefit was also recorded in systemic lupus erythematosus (8 (44.4%) of 18), lichen sclerosus (6 (42.9%) of 14), mastocytosis (2 (33.3%) of 6), necrobiosis lipoidica (4 (30.8%) of 13), granuloma annulare (2 (25%) of 8), scleroderma (2 (22.2%) of 9) and keloids (1 (7.7%) of 13). Overall, treatment was well tolerated with no patients having to stop treatment due to adverse effects.LIMITATIONS: This is a retrospective study with no control group. Subjective/recall bias is quite possible as a number of patients were followed up over the phone.CONCLUSIONS: Our data suggest that ultraviolet A1 can be considered for the treatment of selected dermatoses. However, long-term malignancy risk is as yet unknown.",

keywords = "Atopic dermatitis, morphea, phototherapy, ultraviolet A1",

author = "Attili, {Sasi Kiran} and Dawe, {Robert S.} and Ibbotson, {Sally H.}",

note = "No funding.",

year = "2016",

month = dec,

day = "2",

doi = "10.4103/0378-6323.182805",

language = "English",

volume = "83",

pages = "60--65",

journal = "Indian Journal of Dermatology, Venereology, and Leprology",

issn = "0378-6323",

publisher = "Indian Association of Dermatologists, Venereologists and Leprologists (IADVL)",

number = "1",

}

TY - JOUR

T1 - Ultraviolet A1 phototherapy

T2 - one center's experience

AU - Attili, Sasi Kiran

AU - Dawe, Robert S.

AU - Ibbotson, Sally H.

N1 - No funding.

PY - 2016/12/2

Y1 - 2016/12/2

N2 - BACKGROUND: Ultraviolet A1(UVA1) phototherapy is increasingly being used in the treatment of morphea, atopic dermatitis, lupus and some other recalcitrant dermatoses. We present a retrospective review of our experience with this modality.AIM: To evaluate the treatment response rates for various dermatoses and adverse effects of UVA1 phototherapy.METHODS: We reviewed phototherapy notes along with electronic and/or paper case records for all patients treated with UVA1 phototherapy from October 1996 to December 2008.RESULTS: A total of 269 patients (outcomes available for 247) had 361 treatment courses (treatment data available for 317 courses) over this period. We found phototherapy to be beneficial in 28 (53%) of 53 patients with atopic dermatitis and 19 (51%) of 37 patients with morphea. A beneficial outcome was recorded in all six (100%) cases of urticaria and six (85.7%) of seven patients treated for a polymorphic light eruption. Benefit was also recorded in systemic lupus erythematosus (8 (44.4%) of 18), lichen sclerosus (6 (42.9%) of 14), mastocytosis (2 (33.3%) of 6), necrobiosis lipoidica (4 (30.8%) of 13), granuloma annulare (2 (25%) of 8), scleroderma (2 (22.2%) of 9) and keloids (1 (7.7%) of 13). Overall, treatment was well tolerated with no patients having to stop treatment due to adverse effects.LIMITATIONS: This is a retrospective study with no control group. Subjective/recall bias is quite possible as a number of patients were followed up over the phone.CONCLUSIONS: Our data suggest that ultraviolet A1 can be considered for the treatment of selected dermatoses. However, long-term malignancy risk is as yet unknown.

AB - BACKGROUND: Ultraviolet A1(UVA1) phototherapy is increasingly being used in the treatment of morphea, atopic dermatitis, lupus and some other recalcitrant dermatoses. We present a retrospective review of our experience with this modality.AIM: To evaluate the treatment response rates for various dermatoses and adverse effects of UVA1 phototherapy.METHODS: We reviewed phototherapy notes along with electronic and/or paper case records for all patients treated with UVA1 phototherapy from October 1996 to December 2008.RESULTS: A total of 269 patients (outcomes available for 247) had 361 treatment courses (treatment data available for 317 courses) over this period. We found phototherapy to be beneficial in 28 (53%) of 53 patients with atopic dermatitis and 19 (51%) of 37 patients with morphea. A beneficial outcome was recorded in all six (100%) cases of urticaria and six (85.7%) of seven patients treated for a polymorphic light eruption. Benefit was also recorded in systemic lupus erythematosus (8 (44.4%) of 18), lichen sclerosus (6 (42.9%) of 14), mastocytosis (2 (33.3%) of 6), necrobiosis lipoidica (4 (30.8%) of 13), granuloma annulare (2 (25%) of 8), scleroderma (2 (22.2%) of 9) and keloids (1 (7.7%) of 13). Overall, treatment was well tolerated with no patients having to stop treatment due to adverse effects.LIMITATIONS: This is a retrospective study with no control group. Subjective/recall bias is quite possible as a number of patients were followed up over the phone.CONCLUSIONS: Our data suggest that ultraviolet A1 can be considered for the treatment of selected dermatoses. However, long-term malignancy risk is as yet unknown.

KW - Atopic dermatitis

KW - morphea

KW - phototherapy

KW - ultraviolet A1

UR - http://www.ijdvl.com/aheadofprint.asp

U2 - 10.4103/0378-6323.182805

DO - 10.4103/0378-6323.182805

M3 - Article

C2 - 27212283

SN - 0378-6323

VL - 83

SP - 60

EP - 65

JO - Indian Journal of Dermatology, Venereology, and Leprology

JF - Indian Journal of Dermatology, Venereology, and Leprology

IS - 1

ER -

Ultraviolet A1 phototherapy: one center's experience

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this